Mycobacterium vaccae administration during allergen sensitization or challenge suppresses asthmatic features

J.J. Smit, H. van Loveren, M.O. Hoekstra, M.A. Schijf, G. Folkerts*, F.P. Nijkamp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Mycobacterium vaccae administration during allergen sensitization or challenge suppresses asthmatic features.

Smit JJ, Van Loveren H, Hoekstra MO, Schijf MA, Folkerts G, Nijkamp FP.

Department of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

BACKGROUND AND OBJECTIVE: The hygiene hypothesis suggests that a lack of bacterial infections would favour the development of allergic disease. For this reason, bacteria or their components can be used as potential treatment for allergic asthma. We investigated whether heat-killed Mycobacterium vaccae is either able to suppress the induction of allergic asthma or able to suppress already established allergic asthma. METHODS: Mice were sensitized with ovalbumin (OVA)/alum on days 0 and 14. Thereafter, mice were challenged on days 35, 39 and 42 by inhalation of either OVA or saline aerosols. M. vaccae-treated mice received an injection with 106, 107 or 108 CFU heat-killed M. vaccae on days 0 and 14 or 107 CFU on days 35 and 39. On day 43, the airway responsiveness of the mice to increasing concentrations of methacholine was assessed, blood was withdrawn to measure serum parameters, and lung lavage was performed to detect cytokines and inflammatory cell number. RESULTS: Treatment of OVA-sensitized mice with 107 CFU M. vaccae either during sensitization or challenge suppresses airway hyper-responsiveness, airway eosinophilia and IL-5 production after OVA challenge. The increases in OVA-specific serum IgE and in IL-4 by respiratory challenges with OVA were only diminished after M. vaccae treatment (107 CFU) during sensitization. CONCLUSIONS: Heat-killed M. vaccae prevents allergic and asthmatic manifestations in a mouse model and, more importantly, M. vaccae treatment during challenge suppresses features of asthma, which opens up possibilities for new therapeutic interventions
Original languageEnglish
Pages (from-to)183-189
Number of pages7
JournalClinical and Experimental Allergy
Volume33
Issue number8
DOIs
Publication statusPublished - 1 Jan 2003

Fingerprint

Dive into the research topics of 'Mycobacterium vaccae administration during allergen sensitization or challenge suppresses asthmatic features'. Together they form a unique fingerprint.

Cite this